Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Phase 1 Completed 48 enrolled NGM Biopharmaceuticals, Inc

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Renal Function.

Timeline

Start: 2019-11-08
Primary completion: 2019-12-04
Completion: 2019-12-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aldafermin	Protein / enzyme biologic	3 mg	Subcutaneous

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Summary

Timeline

Drugs

Indications